menu

Clinical Considerations for Targeted Therapies Across Multiple Tumor Types

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Clinical Considerations for Targeted Therapies Across Multiple Tumor Types

close
3 chapters
Play All
0.25 credits
15 minutes
Chapter 1
Clinical Considerations for Targeted Therapies Across Multiple Tumor Types
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Chapter 2
video Mechanism of Action of HER2-Targeting Agents Across Multiple Tumor Types for Segment 11752
Mechanism of Action of HER2-Targeting Agents Across Multiple Tumor Types
Chapter 3
video Mechanisms of Resistance to Anti-HER2 Therapy and Implications for Therapy for Segment 11752
Mechanisms of Resistance to Anti-HER2 Therapy and Implications for Therapy
Details
Presenters
Related
Comments
  • Overview

    Anti-HER2 therapy is well established as a first-line approach for many patients with metastatic breast cancer. HER2 has now been identified as an oncogenic driver across multiple malignancies, including non-small cell lung cancer, colorectal cancer, and gastric cancer. Dr. Sara A. Hurvitz and Dr. Jacob M. Sands discuss the rationale for incorporating the various anti-HER2 therapies in the clinic, and with the use of 3D animation address the emergence of anti-HER2 treatment resistance and novel approaches to overcome that resistance.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Sara A. Hurvitz, MD, FACP
    Associate Professor of Medicine
    UCLA
    Los Angeles, CA

    Contracted Research: Ambrx, Amgen, Arvinas, Bayer, Cascadian, Daiichi Sankyo, Dignitana, Genentech/Roche, GlaxoSmithKline, Immunomedics, Lilly, MacroGenics, Merrimack, Novartis, OBI Pharma, Pfizer, Pieris, Puma Biotechnology, Radius Health, Sanofi, Seattle Genetics
    Consulting Fees: NKMax
    Other: Pfizer, Roche

    Jacob M. Sands, MD
    Physician, Instructor of Medicine
    Dana-Farber Cancer Institute, Harvard Medical School
    Boston, MA

    Consulting Fees: AstraZeneca, Boehringer Ingelheim, Jazz Pharmaceuticals, Lilly, Medtronic, Pharma Mar

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Barry A. Fiedel, PhD, has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Apply best practices in testing for biomarker alterations across multiple tumors
    2. Identify additional mechanisms of resistance that portend a poor prognosis in HER-positive cancers
    3. Identify current and emerging treatments that can overcome resistance mechanisms in HER-positive cancers
  • Target Audience

    This activity is designed to meet the educational needs of oncology and pathology physicians, NPs/PAs, and nurses.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Daiichi Sankyo.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Anti-HER2 therapy is well established as a first-line approach for many patients with metastatic breast cancer. HER2 has now been identified as an oncogenic driver across multiple malignancies, including non-small cell lung cancer, colorectal cancer, and gastric cancer. Dr. Sara A. Hurvitz and Dr. Jacob M. Sands discuss the rationale for incorporating the various anti-HER2 therapies in the clinic, and with the use of 3D animation address the emergence of anti-HER2 treatment resistance and novel approaches to overcome that resistance.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Sara A. Hurvitz, MD, FACP
    Associate Professor of Medicine
    UCLA
    Los Angeles, CA

    Contracted Research: Ambrx, Amgen, Arvinas, Bayer, Cascadian, Daiichi Sankyo, Dignitana, Genentech/Roche, GlaxoSmithKline, Immunomedics, Lilly, MacroGenics, Merrimack, Novartis, OBI Pharma, Pfizer, Pieris, Puma Biotechnology, Radius Health, Sanofi, Seattle Genetics
    Consulting Fees: NKMax
    Other: Pfizer, Roche

    Jacob M. Sands, MD
    Physician, Instructor of Medicine
    Dana-Farber Cancer Institute, Harvard Medical School
    Boston, MA

    Consulting Fees: AstraZeneca, Boehringer Ingelheim, Jazz Pharmaceuticals, Lilly, Medtronic, Pharma Mar

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Barry A. Fiedel, PhD, has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Apply best practices in testing for biomarker alterations across multiple tumors
    2. Identify additional mechanisms of resistance that portend a poor prognosis in HER-positive cancers
    3. Identify current and emerging treatments that can overcome resistance mechanisms in HER-positive cancers
  • Target Audience

    This activity is designed to meet the educational needs of oncology and pathology physicians, NPs/PAs, and nurses.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Daiichi Sankyo.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 9/23/20